Company / Cash & Equivalents
Imunon, Inc. Cash & Equivalents History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$5.8M
FY2023
5-year range
$5.8M / $19.6M
FY2019-FY2023
Trend
-49.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 7 years, ranging from $6M in FY2023 to $20M in FY2021.
Based on SEC 10-K filings.
$6M in FY2023 with a 5-year CAGR of -15.2%.
Declined from $20M to $6M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -30.2%
- 5-Year CAGR
- -15.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -15.2%, indicating a declining trend.
- In FY2023, cash & equivalents decreased 49.2% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $5.8M | -49.2% |
| FY2022 | $11.5M | -41.3% |
| FY2021 | $19.6M | +14.1% |
| FY2020 | $17.2M | +149.7% |
| FY2019 | $6.9M | -48.5% |
| FY2018 | $13.4M | +5.3% |
| FY2015 | $12.7M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026